An observational study in Gastroesophageal Reflux Disease (GERD), Symptom and Musculoskeletal Pain, sponsored by Karabuk University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Karabuk University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Gastroesophageal Reflux with a site in Turkey — 2 open to participants now, 3 under way, none of them phase 3. Gastroesophageal Reflux · Turkey.
Among the 18 studies in Gastroesophageal Reflux with a site in Turkey, this one is the only one that started in 2026, is one of 5 observational ones, and was the 18th registered.
1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.
Browse Gastroesophageal Reflux studies →2 of the 18 studies in Gastroesophageal Reflux with a site in Turkey are open now. Recruiting first, the newest first:
Cleveland Clinic London · Sites in Turkey, Austria, Italy and 4 more countries
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 51 is below the median of 180 across 349 observational studies indexed under Gastroesophageal Reflux.
Median enrollment 48 across the 13 interventional studies, 100 across the 5 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 18 have an industry lead sponsor. The 10 most frequent:
Karabuk University is the lead sponsor of 143 studies on the registry; 39 are open to participants now.
Karabuk University has 3 studies filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
1 of the studies in Gastroesophageal Reflux with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07643779Karabuk UniversitySymptom Severity, Posture, Pain, and Physical Activity in Gastroesophageal Reflux Disease | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Gastroesophageal Reflux with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a cross-sectional research designed to investigate symptom severity, posture, musculoskeletal pain, and physical activity levels in individuals with gastroesophageal reflux disease (GERD).
Symptom severity will be assessed using the GERD-Q and PROMIS GERD scales. Postural assessment will be performed using the Posture Screen Lite application. Musculoskeletal pain will be evaluated with the Visual Analog Scale (VAS) and a body diagram, while physical activity levels will be measured using the International Physical Activity Questionnaire (IPAQ).
The aim of the study is to determine whether GERD is associated not only with gastrointestinal symptoms but also with functional parameters such as posture, pain, and physical activity level.
Patients with and without Gastroesophageal Reflux Disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Age between 18 and 65 years patient who has GERD
Age between 18 and 65 years patient who has not GERD
Gastroesophageal Reflux Disease Questionnaire (GERD-Q)
The GERD-Q is a six-item Likert-type questionnaire that assesses the frequency of GERD-related symptoms over the past week. The first four items evaluate symptom frequency and are used for the diagnosis of the disease and monitoring treatment response. The remaining two items assess the impact of the disease on daily life, including over-the-counter medication use and sleep disturbance. Each item is scored on a four-point scale ranging from 0 to 3 according to symptom frequency. In items 1, 2, 5, and 6, scores increase from 0 to 3 with increasing symptom frequency, whereas in items 3 and 4, scoring is reversed.
Time frame: 1 day
PROMIS GERD Scale
The PROMIS GERD scale consists of 13 items. Each item is scored on a scale ranging from 0 to 4 points, and the total score is obtained by summing all item scores. According to the original scoring system, a score of 0 indicates no symptoms, scores of 1-3 indicate minimal symptoms, scores of 4-7 indicate mild symptoms, scores of 8-15 indicate moderate symptoms, and scores of 16 and above indicate severe symptoms.
Time frame: 1 day
Postural Analysis
Posture Screen Lite is a posture analysis, body composition, and movement assessment software designed for use on iOS and Android devices with built-in camera systems. In this study, posture will be assessed using the iPad-based Posture Screen Lite application. Participants will be assessed wearing appropriate clothing that leaves the upper trunk and lower legs exposed. Photographs will be taken from anterior, posterior, and right and left lateral views using a smartphone, without placing reference markers on the participant beforehand. The captured images will then be analyzed using the Posture Screen Lite software by identifying anatomical reference points on the photographs.
Time frame: 1 day
Visual Analog Scale (VAS)
The Visual Analog Scale (VAS) will be used to assess pain intensity. VAS has been shown to be a valid and reliable method that is sensitive to small changes in clinical pain and treatment-related pain intensity. Participants will be asked to indicate their pain level on a 10-cm horizontal line, ranging from "0" (no pain) to "10" (worst imaginable pain). In addition, participants will mark the location(s) of their pain on a body diagram to determine pain distribution and localization.
Time frame: 1 day
International Physical Activity Questionnaire (IPAQ)
The International Physical Activity Questionnaire (IPAQ) was developed by Craig et al. (2003) to assess physical activity levels. The short form consists of seven items and evaluates physical activity performed during the last seven days. Only activities lasting at least 10 minutes at a time are considered. Participants report the duration (in minutes) of vigorous activities (e.g., weight lifting, fast cycling, aerobic exercises, team sports), moderate activities (e.g., table tennis, folk dances, light load carrying), and walking. These values are converted into metabolic equivalent (MET) scores, and total physical activity level is calculated as MET-min/week. Based on the results, participants can be classified as inactive, minimally active, or highly active.
Time frame: 1 day
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Mar 2027, 3 months later.
Of 95 non-industry observational studies under Gastroesophageal Reflux, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 167. This study's planned 3 months is below that.
Counting every sponsor, half of 117 studies reached it within 45 months; a quarter within 17 and three quarters within 134.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: start Jul 2026 → Nov 2026, primary completion Dec 2026 → Mar 2027 and completion Dec 2026 → Apr 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.